$1.84
Live
0.54%
Downside
Day's Volatility :4.69%
Upside
4.17%
9.23%
Downside
52 Weeks Volatility :91.4%
Upside
90.52%
Period | Nucana Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -39.55% | 3.6% | 0.0% |
6 Months | -52.88% | 10.2% | 0.0% |
1 Year | -86.45% | 19.6% | 0.0% |
3 Years | -97.07% | 16.8% | -23.0% |
Market Capitalization | 4.2M |
Book Value | $1.69 |
Earnings Per Share (EPS) | -17.31 |
Wall Street Target Price | 87.66 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -68.43% |
Return On Equity TTM | -180.77% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -33.2M |
Diluted Eps TTM | -17.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -9.01 |
EPS Estimate Next Year | -8.55 |
EPS Estimate Current Quarter | -2.32 |
EPS Estimate Next Quarter | -2.12 |
What analysts predicted
Upside of 4664.13%
Sell
Neutral
Buy
Nucana Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Nucana Plc | -41.8% | -52.88% | -86.45% | -97.07% | -98.91% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Nucana Plc | NA | NA | NA | -9.01 | -1.81 | -0.68 | NA | 1.69 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Nucana Plc | Buy | $4.2M | -98.91% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Nucana Plc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 169.6%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 141.9%
Baillie Gifford & Co Limited.
The Carlyle Group Inc
Renaissance Technologies Corp
Glass Jacobson Investment Advisors LLC
Morgan Stanley - Brokerage Accounts
Edmond de Rothschild Holding S.A.
nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Organization | Nucana Plc |
Employees | 25 |
CEO | Mr. Hugh Stephen Griffith |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.84
-2.13%
Invesco Bulletshares 2025 Hi
$1.84
-2.13%
Schwab International Dividend Equity Etf
$1.84
-2.13%
Blockchain Coinvestors Acquisition Corp.
$1.84
-2.13%
Allgiant Travel Company
$1.84
-2.13%
Rogers Corp
$1.84
-2.13%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.84
-2.13%
Iheartmedia
$1.84
-2.13%
Lightpath Technologies Inc
$1.84
-2.13%